Steve Schonfeld’s Zevra Therapeutics ZVRA Stock Holding History

Steve Schonfeld’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-13,824	Closed	-$124K	–	2754
2025 Q4	$124K	Buy	+13,824	New	+$131K	﹤0.01%	1789
2023 Q1	–	Sell	-16,200	Closed	-$74.4K	–	2737
2022 Q4	$74.4K	Sell	16,200 -13,600	-46%	-$69.1K	﹤0.01%	2227
2022 Q3	$185K	Sell	29,800 -9,800	-25%	-$55.5K	﹤0.01%	2373
2022 Q2	$177K	Sell	39,600 -4,900	-11%	-$22.3K	﹤0.01%	1945
2022 Q1	$223K	Buy	+44,500	New	+$283K	﹤0.01%	1880

Other funds holding ZVRA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

Steve Schonfeld's ZVRA Position: Q1 2026 in Review

Steve Schonfeld sold out of Zevra Therapeutics (ZVRA) in Q1 2026, closing a stake of 13,824 shares — an estimated $124K sold.

Steve Schonfeld first reported a position in ZVRA in Q1 2022 and held it in 5 quarters. The position peaked at $223K in Q1 2022. 148 funds tracked by Wall St. Rank hold ZVRA as of Q1 2026.

Steve Schonfeld reported no remaining Zevra Therapeutics position as of Q1 2026 after selling out during the quarter.
Steve Schonfeld sold 13,824 Zevra Therapeutics shares in Q1 2026, an estimated $124K.
Steve Schonfeld first reported a position in Zevra Therapeutics in Q1 2022 and held it in 5 quarters.
Steve Schonfeld's Zevra Therapeutics position peaked at $223K in Q1 2022.
148 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.